Published in Arthritis Rheum on February 01, 2005
Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol (2010) 3.56
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) (2009) 2.35
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol (2005) 2.08
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol (2007) 1.69
Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol (2009) 1.60
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis (2006) 1.59
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol (2008) 1.58
In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol (2010) 1.54
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther (2006) 1.42
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? Nat Rev Rheumatol (2009) 1.35
B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol (2009) 1.32
Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther (2011) 1.31
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood (2012) 1.28
Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther (2009) 1.27
Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res (2009) 1.24
Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy. Clin Exp Immunol (2009) 1.23
Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol (2010) 1.21
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2009) 1.21
Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol (2013) 1.18
Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun (2012) 1.15
B cells in autoimmunity. Arthritis Res Ther (2009) 1.13
Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum (2010) 1.13
Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol (2010) 1.11
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol (2009) 1.10
B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev (2008) 1.10
Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. J Virol (2009) 1.09
B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol (2011) 1.08
B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 1.05
A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol (2009) 1.03
NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int (2008) 1.02
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther (2013) 0.99
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity (2010) 0.98
The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int (2007) 0.98
Lupus nephritis: current update. Arthritis Res Ther (2011) 0.97
Importance of B cell co-stimulation in CD4(+) T cell differentiation: X-linked agammaglobulinaemia, a human model. Clin Exp Immunol (2011) 0.97
Editing antigen presentation: antigen transfer between human B lymphocytes and macrophages mediated by class A scavenger receptors. J Immunol (2008) 0.95
Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood (2008) 0.91
Temporal requirements for B cells in the establishment of CD4 T cell memory. J Immunol (2013) 0.89
Decrease in proportion of CD19+ CD24(hi) CD27+ B cells and impairment of their suppressive function in Graves' disease. PLoS One (2012) 0.89
Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clin Exp Nephrol (2010) 0.86
Rationale for B cell targeting in SLE. Semin Immunopathol (2014) 0.86
Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol (2010) 0.85
CD19 and CD32b differentially regulate human B cell responsiveness. J Immunol (2014) 0.85
Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica (2011) 0.83
B cell deficient mice are protected from biliary obstruction in the rotavirus-induced mouse model of biliary atresia. PLoS One (2013) 0.82
Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum (2005) 0.82
Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution. Pediatr Nephrol (2008) 0.80
[Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus]. Z Rheumatol (2007) 0.80
Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 0.79
Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. Rheumatol Int (2007) 0.79
Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosis. Arthritis Res Ther (2009) 0.78
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab. Biologics (2012) 0.78
Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol Int (2011) 0.78
Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab. BMC Nephrol (2011) 0.77
B cell modulation in rheumatology. Curr Opin Pharmacol (2007) 0.77
Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2010) 0.76
Rituximab Treatment for Nephrotic Syndrome in Children. Curr Pediatr Rep (2015) 0.76
Cell biology and genetics of minimal change disease. F1000Res (2016) 0.76
Developments in lupus 2006. Arthritis Res Ther (2007) 0.75
A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. Arthritis Res Ther (2016) 0.75
In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al. Arthritis Rheum (2005) 0.75
CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients. PeerJ (2016) 0.75
Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab. Blood Res (2016) 0.75
Depletion of B lymphocytes in idiopathic membranous glomerulopathy: results from patients with extended follow-up. Nephron Extra (2013) 0.75
B cell immunology for the clinician. Pediatr Infect Dis J (2011) 0.75
Efficient Culture of Human Naive and Memory B Cells for Use as APCs. J Immunol (2016) 0.75
Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol (2013) 0.75
The Role of TLR4 on B Cell Activation and Anti-β2GPI Antibody Production in the Antiphospholipid Syndrome. J Immunol Res (2016) 0.75
Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters. Clin Rheumatol (2014) 0.75
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum (1993) 7.14
Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med (1979) 5.58
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J Immunol (1977) 2.06
The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis (1994) 2.03
Genetic differences between primary and secondary sicca syndrome. N Engl J Med (1979) 1.93
Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med (1979) 1.79
Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int (2007) 1.77
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum (2000) 1.74
Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum (1982) 1.73
Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol (1993) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Hypokalaemic paralysis as the presenting manifestation of primary Sjögren's syndrome. Nephrol Dial Transplant (1994) 1.62
High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol (1987) 1.59
Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis (1985) 1.56
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
Lymphoma development in Sjögren's syndrome: novel p53 mutations. Arthritis Rheum (1999) 1.53
Sjögren's syndrome in patients with the CREST variant of progressive systemic scleroderma. J Rheumatol (1991) 1.51
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int (2000) 1.50
Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol (1979) 1.46
Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol (2007) 1.44
Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma. Scand J Rheumatol (2011) 1.41
Antiphospholipid syndrome: clinical and therapeutic aspects. Lupus (1994) 1.39
The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol (2002) 1.39
Necrotizing vasculitis in Greece: clinical, immunological and immunogenetic aspects. A study of 66 patients. Br J Rheumatol (1997) 1.39
Respiratory manifestations in primary Sjögren's syndrome. A clinical, functional, and histologic study. Chest (1985) 1.37
Preliminary diagnostic criteria for Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 1.37
Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) (2000) 1.36
Kidney involvement in primary Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 1.33
Sjögren's syndrome association with HLA-Dw3. N Engl J Med (1977) 1.32
Diffuse fasciitis with eosinophilia. A clinicopathologic study. Am J Med (1980) 1.31
Sjögren's syndrome: a defect in reticuloendothelial system Fc-receptor-specific clearance. Ann Intern Med (1979) 1.29
Sjögren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med (1977) 1.27
Central nervous system involvement in Sjogren's syndrome. Ann Rheum Dis (2004) 1.26
HLA-DR expression by labial minor salivary gland tissues in Sjögren's syndrome. Ann Rheum Dis (1986) 1.25
Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum (1996) 1.23
Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum (1996) 1.23
Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum (1981) 1.21
Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J (2008) 1.21
Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J (2009) 1.21
Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology (1990) 1.19
Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome. Clin Exp Immunol (2007) 1.17
T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjögren's syndrome. J Rheumatol (1991) 1.17
Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. Ann Rheum Dis (2004) 1.14
Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med (1977) 1.14
Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis (2006) 1.12
CBA/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice. J Exp Med (1979) 1.12
Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM (2000) 1.12
Erythema nodosum: the underlying conditions. Clin Rheumatol (2000) 1.11
Renal tubular acidosis in primary Sjögren's syndrome. Clin Rheumatol (1992) 1.11
Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol (1995) 1.10
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) (2001) 1.10
Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin Exp Rheumatol (1985) 1.10
Liver involvement in primary Sjögren's syndrome. Br J Rheumatol (1994) 1.09
Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.09
Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) (2004) 1.09
Demonstration and identification of monoclonal proteins in the urine of patients with Sjögren's syndrome. Ann Rheum Dis (1985) 1.09
Echocardiographic identification of cardiac abnormality in scleroderma and related disorders. Am J Med (1979) 1.09
Serological profiles in subgroups of patients with Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 1.08
Modes of epithelial cell death and repair in Sjögren's syndrome (SS). Clin Exp Immunol (1998) 1.08
Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. Clin Immunol Immunopathol (1987) 1.07
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) (1999) 1.06
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum (2007) 1.06
CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome. Clin Exp Immunol (1999) 1.06
Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus (1993) 1.06
"Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum (2001) 1.06
Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis (1999) 1.05
Prevalence of Sjögren's syndrome in a closed rural community. Ann Rheum Dis (1997) 1.05
Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun (2012) 1.04
CD5-expressing B lymphocytes in the blood and salivary glands of patients with primary Sjögren's syndrome. J Autoimmun (1988) 1.03
The spectrum of neurological involvement in Sjögren's syndrome. Br J Rheumatol (1990) 1.03
Sjögren's syndrome: autoimmune epithelitis. Baillieres Best Pract Res Clin Rheumatol (2000) 1.03
Oligoclonal immunoglobulins in patients with the acquired immunodeficiency syndrome. Clin Immunol Immunopathol (1985) 1.02
The clinical picture of primary Sjögren's syndrome: a retrospective study. J Rheumatol (1983) 1.01
Presence of intracytoplasmic IgG in the lymphocytic infiltrates of the minor salivary glands of patients with primary Sjögren's syndrome. Clin Exp Rheumatol (1985) 1.01
Detection of anti-Ro(SSA) antibodies in autoimmune diseases: comparison of five methods. Br J Rheumatol (1993) 1.01
Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med (2000) 1.00
Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum (2009) 1.00
Secondary Sjögren's syndrome in rheumatoid arthritis. J Rheumatol (1987) 1.00
Vasculitis in primary Sjögren's syndrome. Histologic classification and clinical presentation. Am J Clin Pathol (1987) 1.00
Evaluation of tear break-up time, Schirmer's-I test and rose bengal staining as confirmatory tests for keratoconjunctivitis sicca. Clin Exp Rheumatol (1989) 1.00
Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun (1999) 0.99
Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4. J Immunol (2001) 0.99
Pulmonary and gastrointestinal manifestations of Sjögren's syndrome. Rheum Dis Clin North Am (1992) 0.99
High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren's syndrome. J Immunol (1983) 0.99
The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis (2000) 0.98
Middle ear function in patients with juvenile chronic arthritis. Ann Rheum Dis (1990) 0.98
Enzyme immunoassays for the detection of IgG and IgM anti-dsDNA antibodies: clinical significance and specificity. Clin Exp Rheumatol (1988) 0.98
Fine specificity of autoantibodies to La/SSB: epitope mapping, and characterization. Clin Exp Immunol (1997) 0.98
Prevalence of primary Sjögren's syndrome in an elderly population. Br J Rheumatol (1988) 0.98
Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol (1997) 0.98